Shah TT, et al. - Via a prospective registry-based case series of 122 consecutive patients undergoing focal cryotherapy, which could be used to treat patients with clinically significant nonmetastatic prostate cancer to reduce side effects, the researchers intended to determine the early-medium-term cancer control and its functional outcomes. Eighty patients with anterior ablation, 23 combined posterior and anterior ablation, and two posterior ablations alone were observed. Whilst failure-free survival was approximately 90%, no patient died from prostate cancer. Hence, focal cryotherapy primarily for anterior intermediate and high-risk prostate cancer was observed by the contributors resulting in good rates of cancer control and low rates of treatment-related side effects.